All In Biotech

Drug Trial Radar · NCT05277051

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

152

Actual

Start

Mar 22, 2022

Primary completion

Jun 30, 2026

Study completion Aug 31, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.

Conditions

  • Neoplasms

Interventions

  • RemzistotugDrug

    Remzistotug will be administered.

  • DostarlimabDrug

    Dostarlimab will be administered.

  • BelrestotugDrug

    Belrestotug will be administered.

  • NelistotugDrug

    Nelistotug will be administered.

  • GSK5764227Drug

    GSK5764227 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arms A, B, C, I: Number of Participants with dose-limiting toxicities (DLTs)Time frame: Up to 21 days
  2. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 27 months

Locations

26 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Oklahoma City, Oklahoma

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Salt Lake City, Utah

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Ottawa, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Chengdu, China

  • GSK Investigational Site

    Jinan, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Wuhan, China

  • GSK Investigational Site

    Dijon, France

  • GSK Investigational Site

    Lille, France

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Málaga, Spain

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.